Skip to main content
. 2022 Dec 14;67:1–7. doi: 10.1016/j.breast.2022.12.006

Table 1.

Clinicopathological parameters of included patients divided by HER2 status.

Variable HER2-low
HER2-zero
Overall
p
(n = 234) (n = 91) (n = 325)
Age (median [IQR]) 47.0 [40.0, 53.0] 46.0 [38.0, 54.0] 46.0 [40.0, 53.0] 0.6457†
HR Status (%).
 Negative 87 (37.2) 54 (59.3) 141 (43.4) 0.0005‡
 Positive 147 (62.8) 37 (40.7) 184 (56.6)
Grading (%).
 Grade Ⅰ 19 (8.1) 1 (1.1) 20 (6.2) 0.0048※
 Grade Ⅱ 105 (44.9) 29 (31.9) 134 (41.2)
 Grade Ⅲ 55 (23.5) 31 (34.1) 86 (26.5)
 Missing 55 (23.5) 30 (33.0) 85 (26.2)
T stage (%).
 cT1 10 (4.3) 6 (6.6) 16 (4.9) 0.7413
 cT2 130 (55.6) 54 (59.3) 184 (56.6)
 cT3 57 (24.4) 17 (18.7) 74 (22.8)
 cT4 33 (14.1) 13 (14.3) 46 (14.2)
 Missing 4 (1.7) 1 (1.1) 5 (1.5)
N stage (%).
 cN0 33 (14.1) 13 (14.3) 46 (14.2) 0.8319
 cN1-3 198 (84.6) 76 (83.5) 274 (84.3)
 Missing 3 (1.3) 2 (2.2) 5 (1.5)
Clinical Stage (%).
 1 2 (0.9) 1 (1.1) 3 (0.9) 0.4708
 2 88 (37.6) 37 (40.7) 125 (38.5)
 3 140 (59.8) 49 (53.8) 189 (58.2)
 Missing 4 (1.7) 4 (4.4) 8 (2.5)
Histological Type (%).
 No special type 6 (2.6) 4 (4.4) 287 (88.3) 0.5166
 Invasive lobular 206 (88.0) 81 (89.0) 10 (3.1)
 Other 22 (9.4) 6 (6.6) 28 (8.6)
AR status (%).
 Positive 115 (49.1) 49 (53.8) 76 (23.4) 0.4569
 Negative 59 (25.2) 17 (18.7) 164 (50.5)
 Missing 60 (25.6) 25 (27.5) 85 (26.2)
Ki67 status (%).
 ≤20% 67 (28.6) 15 (16.5) 82 (25.2) 0.0072
 20.1%–30.0% 40 (17.1) 8 (8.8) 48 (14.8)
 >30% 126 (53.8) 68 (74.7) 194 (59.7)
 Missing 1 (0.4) 0 (0.0) 1 (0.3)

Data are described as n (%) or median [IQR]. †Mann-Whitney test for continuous data. ‡Fisher's exact test for data with 2 categories. ※χ2 test for data with more than two categories. HR: hormone receptor; AR: androgen receptor.